Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.
2.

Promyelocytic sarcoma of the right humerus: an unusual clinical presentation with unique diagnostic and treatment considerations.

Sawhney S, Holtzman NG, Davis DL, Kaizer H, Giffi V, Emadi A, Koka R.

Clin Case Rep. 2017 Sep 29;5(11):1874-1877. doi: 10.1002/ccr3.1212. eCollection 2017 Nov.

3.

Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.

Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Merwe I, Philip S, Imran M, Yu SL, Li H, Amrein PC, Duong VH, Sausville EA, Baer MR, Fathi AT, Singh Z, Bentzen SM.

Cancer Chemother Pharmacol. 2018 Jan;81(1):217-222. doi: 10.1007/s00280-017-3459-6. Epub 2017 Nov 8.

PMID:
29119293
4.

Breaking Mitochondrial Fasting for Cancer Treatment: Old Wine in New Bottles.

Emadi A, Lapidus RG.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx069. No abstract available.

PMID:
29059434
5.
6.

Inappropriate Packed RBC Transfusion in a Tertiary Care Center.

Sadeghi A, Belali S, Ali Asgari A, Morovat Z, Malekzadeh R, Emadi A.

Arch Iran Med. 2017 Feb;20(2):83-85. doi: 0172002/AIM.004.

7.

Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells.

Carter-Cooper BA, Fletcher S, Ferraris D, Choi EY, Kronfli D, Dash S, Truong P, Sausville EA, Lapidus RG, Emadi A.

Bioorg Med Chem Lett. 2017 Jan 1;27(1):6-10. doi: 10.1016/j.bmcl.2016.11.045. Epub 2016 Nov 17.

8.

Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.

Alshemmari SH, Rajan R, Emadi A.

Med Princ Pract. 2016;25(6):501-509. Epub 2016 Sep 21. Review.

9.

Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.

Emadi A, Bade NA, Stevenson B, Singh Z.

Pharmaceuticals (Basel). 2016 Mar 10;9(1). pii: E12. doi: 10.3390/ph9010012.

10.

Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.

Babakoohi S, Lapidus RG, Faramand R, Sausville EA, Emadi A.

Appl Immunohistochem Mol Morphol. 2017 May/Jun;25(5):334-337. doi: 10.1097/PAI.0000000000000342. Review.

PMID:
26945443
11.

Dr. Amir Masoud Emadi.

Emadi A, Malekzadeh R.

Arch Iran Med. 2016 Feb;19(2):163. doi: 0161902/AIM.0017. No abstract available.

12.

A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone.

Pidugu LS, Mbimba JC, Ahmad M, Pozharski E, Sausville EA, Emadi A, Toth EA.

BMC Struct Biol. 2016 Jan 28;16:1. doi: 10.1186/s12900-016-0052-x.

13.

Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2.

Lapidus RG, Carter-Cooper BA, Sadowska M, Choi EY, Wonodi O, Muvarak N, Natarajan K, Pidugu LS, Jaiswal A, Toth EA, Rassool FV, Etemadi A, Sausville EA, Baer MR, Emadi A.

Pharmaceuticals (Basel). 2016 Jan 19;9(1). pii: E4. doi: 10.3390/ph9010004.

14.

Reverse Pseudohyperkalemia: An Important Clinical Entity in Chronic Lymphocytic Leukemia.

Mansoor S, Holtzman NG, Emadi A.

Case Rep Hematol. 2015;2015:930379. doi: 10.1155/2015/930379. Epub 2015 Sep 27.

15.

Exploiting AML vulnerability: glutamine dependency.

Emadi A.

Blood. 2015 Sep 10;126(11):1269-70. doi: 10.1182/blood-2015-07-659508. No abstract available.

16.

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.

Fathi AT, Wander SA, Faramand R, Emadi A.

Semin Hematol. 2015 Jul;52(3):165-71. doi: 10.1053/j.seminhematol.2015.03.002. Epub 2015 Mar 17. Review.

PMID:
26111463
17.

Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.

Emadi A, Sadowska M, Carter-Cooper B, Bhatnagar V, van der Merwe I, Levis MJ, Sausville EA, Lapidus RG.

Leuk Res. 2015 Jul;39(7):719-29. doi: 10.1016/j.leukres.2015.04.002. Epub 2015 Apr 30.

PMID:
25982179
18.

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.

Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA.

Am J Hematol. 2015 May;90(5):E77-9. doi: 10.1002/ajh.23965. Epub 2015 Feb 27.

19.

Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study.

Etemadi A, Kamangar F, Islami F, Poustchi H, Pourshams A, Brennan P, Boffetta P, Malekzadeh R, Dawsey SM, Abnet CC, Emadi A.

BMC Med. 2015 Jan 15;13:8. doi: 10.1186/s12916-014-0237-8.

20.

Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis.

Bhatnagar V, Adelakun A, Kendall T, Holtzman N, Farshidpour M, Stevenson B, Chen Q, Emadi A.

Arch Iran Med. 2015 Jan;18(1):65-8. doi: 0151801/AIM.0015.

Supplemental Content

Loading ...
Support Center